Table 2.

Viral response and outcomes

PatientViral load immediately before first VST, cp/mLDay post- HSCT at first VST infusionVST infusions, nVST product infusedHLA match (VSTs to patient)HLA antigen/allele(s) matched between VST and patient*Best responsePost–VST course and outcome after best responseRehospitalization post–VST infusion, dStatus, cause of death (days post–first VST infusion)
1 55 000 171 3 2011-18, RPT 4/6 (A1, A1, B8, DR 03:01)1,2 PR Progressive viremia. Additional VST. Antivirals after final VST infusion. Persistent viremia. 69 Death, presumed CMV disease (209) 
13-0008 3/6 (A1, B8, DR 03:01)3 
2 <150 83 4 12-0022, RPT, RPT 2/6 (B7, DR 15:01)1-3 CR Quantifiable reactivation. Additional VSTs/antivirals. No antivirals restarted after final VST infusion, despite persisting viremia. NA Alive 
13-0008† 3/6 (A1, B8, DR 03:01)4 
3 <150 63 2 12-0022, 4/6 (A2, A2, B7, DR 07:01)1 CR‡ Reactivation (BLQ), no additional VSTs/antivirals. NA Alive 
13-0006 2/6 (A2, B7)2 
4 1440 52 1 12-0022 4/6 A2, A2, B7, DR 15:01 CR Antivirals after final VST infusion. CR attained. Quantifiable reactivation. No additional antivirals. NA Alive 
5 <150 81 1 13-0015 3/6 B35, DR 01:01, DR 04:01 CR Reactivation (BLQ). No additional VSTs/antivirals. 6 Alive 
6 363 69 2 13-0019§, RPT§ 3/6 A2, A2, DR 11:01 CR Reactivation (BLQ). No additional VSTs/antivirals. 14 Alive 
7 <150 122 1 14-0004 4/6 A1, B8, DR 07:01, DR 07:01 CR Quantifiable reactivation. No additional VSTs/antivirals. 3 Alive 
8 270 66 2 14-0006, RPT† 3/6 A2, B44, DR 04:01 CR Sustained CR. NA Alive 
9 4680 67 1 13-0015 2/6 B35||, DR 01:01|| PR Progressive viremia and CMV colitis. Not fit for additional VSTs/antivirals. 20 Death, bacterial infection (71) 
10 5000 69 1 13-0015 2/6 A2, B35 CR Reactivation (BLQ). No additional VSTs/antivirals. NA Alive 
11 12 900 62 1 14-0008 2/6 A24, B40 CR Antivirals after final VST infusion. CR attained. No additional antivirals. Did not leave hospital Death, gut GVHD + disseminated adenoviral infection (35) 
12 660 67 1 14-0007 2/6 B8||, DR 03:01|| CR Reactivation (BLQ). Antivirals restarted after final VST infusion. 30 Alive 
13 1740 62 1 14-0007 3/6 A1, B8, DR 03:01 PR Decreasing viral load. No additional VSTs/antivirals. Did not leave hospital Death, disseminated toxoplasmosis (33) 
14 281 69 2 13-0015 2/6 (A2, DR 04:01)1 NR Stable viremia. No antivirals after final VST infusion. 6 Alive 
14-0010 1/6 (A2)2 
15 11 900 161 2 13-0015 3/6 (A2, B35, DR 01:01)1 CR Sustained CR. 9 Death, relapse (190) 
13-0019 2/6 (A2, A2)2 
16 60 300 126 1 14-0003 1/6 B7 CR Quantifiable reactivation. No additional VSTs/antivirals. NA Alive 
17 9800 104 2 14-0004, RPT 3/6 A1, DR 07:01, DR 07:01 PR Progressive viremia. Additional VSTs, no additional antivirals. 15 Death, bacterial infection (37) 
18 386 153 1 14-0004 2/6 A1, B8 CR Quantifiable reactivation. No additional VSTs/antivirals. 8 Alive 
19 1940 349 2 13-0015, RPT† 3/6 A2, B35, DR 01:01 CR CMV enteritis post–first VST infusion, treated with additional VSTs. CR attained. Quantifiable reactivation. No additional VSTs/antivirals. 5 Alive 
20 3260 118 4 14-0010, RPT† 1/6 (A2)1,2 CR Quantifiable reactivation. Additional VSTs/antivirals. No antivirals restarted after final VST infusion. 40 Alive/Relapse 
13-0006§ 2/6 (A2, DR 04:01)3 
13-0019 2/6 (A2, A2)4 
21 51700 132 3 14-0007, RPT† 3/6 (A1, B8, DR 03:01)all CR Quantifiable reactivation. Additional VSTs/antivirals. No antivirals restarted after final VST infusion. NA Alive 
13-0008 3/6 
22 897 89 1 14-0007 3/6 A1, A31, B40 CR Sustained CR. NA Alive 
23 6100 37 1 13-0015 2/6 B35, DR 01:01 CR Sustained CR. 3 Alive 
24 8500 124 2 14-0003, RPT 2/6 B7, DR 14:54|| CR Antivirals after final VST infusion. CR attained. No additional antivirals. 59 Death, CNS EBV PTLD (80) 
25 2300 102 1 14-0004§ 3/6 A1, DR 07:01, DR 07:01 CR Reactivation (BLQ). No additional VSTs/antivirals. NA Alive 
26 150 57 2 14-0007, RPT† 1/6 DR 01:01 CR Quantifiable reactivation. Additional VSTs, no antivirals. No antivirals after final VST infusion. 11 Alive 
27 1260 68 2 13-0005 1/6 (A1)all CR Reactivation (BLQ). No additional VSTs/antivirals. NA Alive 
13-0008 1/6 
28 483 47 1 13-0019 3/6 A2, A2, B40 PR Decreasing viral load. Off study 10 days post–VST infusion. NA Death, relapse (58) 
29 389 045 42 1 14-0002 1/6 DR 01:01 CR Reactivation (BLQ). No additional VSTs/antivirals. NA Alive 
30 81 240 133 1 13-0029 1/6 A24 NR Progressive viremia. Not fit for additional VSTs/antivirals. Did not leave hospital Death, relapse (14) 
PatientViral load immediately before first VST, cp/mLDay post- HSCT at first VST infusionVST infusions, nVST product infusedHLA match (VSTs to patient)HLA antigen/allele(s) matched between VST and patient*Best responsePost–VST course and outcome after best responseRehospitalization post–VST infusion, dStatus, cause of death (days post–first VST infusion)
1 55 000 171 3 2011-18, RPT 4/6 (A1, A1, B8, DR 03:01)1,2 PR Progressive viremia. Additional VST. Antivirals after final VST infusion. Persistent viremia. 69 Death, presumed CMV disease (209) 
13-0008 3/6 (A1, B8, DR 03:01)3 
2 <150 83 4 12-0022, RPT, RPT 2/6 (B7, DR 15:01)1-3 CR Quantifiable reactivation. Additional VSTs/antivirals. No antivirals restarted after final VST infusion, despite persisting viremia. NA Alive 
13-0008† 3/6 (A1, B8, DR 03:01)4 
3 <150 63 2 12-0022, 4/6 (A2, A2, B7, DR 07:01)1 CR‡ Reactivation (BLQ), no additional VSTs/antivirals. NA Alive 
13-0006 2/6 (A2, B7)2 
4 1440 52 1 12-0022 4/6 A2, A2, B7, DR 15:01 CR Antivirals after final VST infusion. CR attained. Quantifiable reactivation. No additional antivirals. NA Alive 
5 <150 81 1 13-0015 3/6 B35, DR 01:01, DR 04:01 CR Reactivation (BLQ). No additional VSTs/antivirals. 6 Alive 
6 363 69 2 13-0019§, RPT§ 3/6 A2, A2, DR 11:01 CR Reactivation (BLQ). No additional VSTs/antivirals. 14 Alive 
7 <150 122 1 14-0004 4/6 A1, B8, DR 07:01, DR 07:01 CR Quantifiable reactivation. No additional VSTs/antivirals. 3 Alive 
8 270 66 2 14-0006, RPT† 3/6 A2, B44, DR 04:01 CR Sustained CR. NA Alive 
9 4680 67 1 13-0015 2/6 B35||, DR 01:01|| PR Progressive viremia and CMV colitis. Not fit for additional VSTs/antivirals. 20 Death, bacterial infection (71) 
10 5000 69 1 13-0015 2/6 A2, B35 CR Reactivation (BLQ). No additional VSTs/antivirals. NA Alive 
11 12 900 62 1 14-0008 2/6 A24, B40 CR Antivirals after final VST infusion. CR attained. No additional antivirals. Did not leave hospital Death, gut GVHD + disseminated adenoviral infection (35) 
12 660 67 1 14-0007 2/6 B8||, DR 03:01|| CR Reactivation (BLQ). Antivirals restarted after final VST infusion. 30 Alive 
13 1740 62 1 14-0007 3/6 A1, B8, DR 03:01 PR Decreasing viral load. No additional VSTs/antivirals. Did not leave hospital Death, disseminated toxoplasmosis (33) 
14 281 69 2 13-0015 2/6 (A2, DR 04:01)1 NR Stable viremia. No antivirals after final VST infusion. 6 Alive 
14-0010 1/6 (A2)2 
15 11 900 161 2 13-0015 3/6 (A2, B35, DR 01:01)1 CR Sustained CR. 9 Death, relapse (190) 
13-0019 2/6 (A2, A2)2 
16 60 300 126 1 14-0003 1/6 B7 CR Quantifiable reactivation. No additional VSTs/antivirals. NA Alive 
17 9800 104 2 14-0004, RPT 3/6 A1, DR 07:01, DR 07:01 PR Progressive viremia. Additional VSTs, no additional antivirals. 15 Death, bacterial infection (37) 
18 386 153 1 14-0004 2/6 A1, B8 CR Quantifiable reactivation. No additional VSTs/antivirals. 8 Alive 
19 1940 349 2 13-0015, RPT† 3/6 A2, B35, DR 01:01 CR CMV enteritis post–first VST infusion, treated with additional VSTs. CR attained. Quantifiable reactivation. No additional VSTs/antivirals. 5 Alive 
20 3260 118 4 14-0010, RPT† 1/6 (A2)1,2 CR Quantifiable reactivation. Additional VSTs/antivirals. No antivirals restarted after final VST infusion. 40 Alive/Relapse 
13-0006§ 2/6 (A2, DR 04:01)3 
13-0019 2/6 (A2, A2)4 
21 51700 132 3 14-0007, RPT† 3/6 (A1, B8, DR 03:01)all CR Quantifiable reactivation. Additional VSTs/antivirals. No antivirals restarted after final VST infusion. NA Alive 
13-0008 3/6 
22 897 89 1 14-0007 3/6 A1, A31, B40 CR Sustained CR. NA Alive 
23 6100 37 1 13-0015 2/6 B35, DR 01:01 CR Sustained CR. 3 Alive 
24 8500 124 2 14-0003, RPT 2/6 B7, DR 14:54|| CR Antivirals after final VST infusion. CR attained. No additional antivirals. 59 Death, CNS EBV PTLD (80) 
25 2300 102 1 14-0004§ 3/6 A1, DR 07:01, DR 07:01 CR Reactivation (BLQ). No additional VSTs/antivirals. NA Alive 
26 150 57 2 14-0007, RPT† 1/6 DR 01:01 CR Quantifiable reactivation. Additional VSTs, no antivirals. No antivirals after final VST infusion. 11 Alive 
27 1260 68 2 13-0005 1/6 (A1)all CR Reactivation (BLQ). No additional VSTs/antivirals. NA Alive 
13-0008 1/6 
28 483 47 1 13-0019 3/6 A2, A2, B40 PR Decreasing viral load. Off study 10 days post–VST infusion. NA Death, relapse (58) 
29 389 045 42 1 14-0002 1/6 DR 01:01 CR Reactivation (BLQ). No additional VSTs/antivirals. NA Alive 
30 81 240 133 1 13-0029 1/6 A24 NR Progressive viremia. Not fit for additional VSTs/antivirals. Did not leave hospital Death, relapse (14) 

BLQ, below level of quantitation; CNS, central nervous system; cp, copies; NA, not applicable; RPT, repeat infusion of the same VST product.

*

In column 7, HLA match was low resolution for HLA-A and B and allelic for DRB1. Antigens or alleles with HLA-restricted viral activity are marked in bold. Superscript outside parenthesis refers to the VST infusion number (e.g. 1 indicates first infusion).

†

Infusion dose >2.0 × 107 cells/m2 (range, 3.1 to 5.0 × 107/m2).

‡

CR achieved before donor lymphocyte infusions administered for relapse prophylaxis on day 117 and 178 post–first VST infusion.

§

Infusion dose <2.0 × 107 cells/m2 (range, 1.37 to 1.65 ×107/m2).

||

HLA allele of product matched to HLA allele of recipient (not transplant donor).

HLA allele of product matched to HLA allele of transplant donor (not recipient).

View Large
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal